Summit Therapeutics presented data at the World Conference on Lung Cancer showing that their experimental drug ivonescimab outperformed Merck’s Keytruda in a late-stage trial for lung cancer. The Phase 3 study, HARMONi-2, conducted by Akeso, enrolled nearly 400 patients with advanced non-small cell lung cancer. Ivonescimab reduced the risk of tumor progression by 49% compared to Keytruda, with patients experiencing a median progression-free survival of 11.1 months versus 5.8 months on Keytruda. This marks a significant achievement in the field of cancer immunotherapy, challenging the dominance of Keytruda and potentially offering a new treatment option for patients.
Source link
Summit therapy beat Merck blockbuster Keytruda in late-stage lung cancer trial
